Clinical trials: Cancer of the Esophagus
Esophageal Cancer
Decreasing Postoperative Complications by Goal-Directed Fluid Therapy During Esophageal Resection
Surgery for cancer of the esophagus is associated with a high risk of postoperative complications. It has been shown that the risk of postoperative complications can be decreased by optimising the amount and type of infusion…
- Trial name
- NCT01416077
- Testing
- fluid optimisation
- Where
- Sweden
- Volunteers
- 64 people
- Sponsor
- University Hospital, Linkoeping
Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Participants will receive study treatment with agenT-797, botensilimab, balstilimab, ramucirumab, and paclitaxel. When participants start each agent will depend on how their disease is affecting them.
- Conditions
- Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT06251973
- Testing
- AgenT-797, Botensilimab, Balstilimab
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00757172
- Testing
- panitumumab, cisplatin, docetaxel
- Where
- 21 sites in United States
- Volunteers
- 70 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Locally Advanced Esophageal or GE Junction Cancer
Hypofractionated Definitive Chemoradiotherapy for Oesophageal Cancer
The goal of this clinical trial is to learn if hypofractionation of definitive chemoradiotherapy can treat patients with locally advanced esophageal cancer.
- Trial name
- HYROC (NCT07632079)
- Testing
- Hypofractionation, carboplatin + paclitaxel (CP)
- Where
- 7 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)
Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract
Primary objective: To determine the Phase II doses and to evaluate the safety of administering bexarotene (Targretin®) daily in combination with oral erlotinib (Tarceva™) to patients with advanced aerodigestive tract cancers.
- Trial name
- NCT01116622
- Testing
- Bexarotene (Targretin®), Erlotinib (Tarceva™)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
- Conditions
- Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05795595
- Testing
- CTX131
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- CRISPR Therapeutics AG
Thoracic Cancer, Lung Cancer
Reirradiation Dose Escalation in Thoracic Cancers
This is a study involving patients with recurrence, metastasis, or new primary malignancies in the thorax requiring radiation and who have previously received radiotherapy to the thorax, where re-irradiation is expected to exceed…
- Conditions
- Thoracic Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- REPAIR (NCT06558175)
- Testing
- stereotactic body radiation therapy (SBRT)
- Volunteers
- 48 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Barrett's Esophagus, Overweight and Obesity
CAlorie and Protein REstriction PROgram in Barrett's Esophagus Patients (CARE-PRO).
The increasing incidence of Esophageal Adenocarcinoma (EAC) in several Western countries can be primarily ascribed to risk factors such as obesity, chronic gastroesophageal reflux, dietary habits and alcohol intake.
- Trial name
- CARE-PRO (NCT03813381)
- Testing
- Calorie and protein restriction diet
- Volunteers
- 160 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Esophageal Cancer, Non-small Cell Lung Cancer
Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET
The goal of this research study is to learn if a new type of PET scan (18F-FLT) can help to better detect changes of tumor growth rate (or how active) in esophagus cancer and lung cancer Researchers will study at what time during…
- Trial name
- NCT01065818
- Testing
- Fluoro-L-Thymidine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Esophageal Squamous Cell Carcinoma, Oligometastatic Disease
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
Patients with oligometastatic squamous cell carcinoma were enrolled and randomly assigned to receive either PD-1 inhibitor +/- chemotherapy combined with local therapy or PD-1 inhibitor +/- chemotherapy alone.
- Conditions
- Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy
- Trial name
- NCT06190782
- Testing
- PD-1 inhibitor+/- chemotherapy combined with local therapy, systemic therapy alone
- Where
- China
- Volunteers
- 354 people
- Sponsor
- Fudan University
EGFR Overexpression, Locally Advanced Solid Tumor
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can…
- Conditions
- EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT06975410
- Testing
- YH32364
- Where
- 4 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Yuhan Corporation
Esophageal Cancer, Gastric Cancer
VITAMin Insufficiency in Esophagogastric Neoplasms
Rationale: Esophageal cancer and gastric cancer are among the top ten most common cancers worldwide. Both diseases have major impact on the nutritional status of patients and their quality of life.
- Conditions
- Esophageal Cancer, Gastric Cancer, Vitamin Disease, Quality of Life
- Trial name
- VITAMIN (NCT05281380)
- Testing
- GIKAVI
- Where
- Netherlands
- Volunteers
- 107 people
- Sponsor
- Zuyderland Medisch Centrum
Esophageal Cancer, Gastric Cancer
Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have locally…
- Trial name
- NCT00005876
- Testing
- rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Esophageal Cancer
Simultaneous Integrated Boost (SIB) in Esophageal Cancer
The goal of this clinical research study is to find the highest tolerable dose of radiation that can be given in combination with chemotherapy in patients with esophageal cancer that cannot be removed by surgery.
- Trial name
- NCT01102088
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Cancer
Effect of Postoperative Family Nutrition Mode on Weight/BMI of Patients With Esophageal Cancer
This clinical trial is designed to be a multi-center prospective observational study which shall compare the effect of different postoperative home nutrition modes on recent nutritional index (weight/BMI) of patients with…
- Trial name
- NCT03286920
- Testing
- Oral nutrition supplement, Tube feeding nutrition supplement
- Where
- 23 sites in China
- Volunteers
- 600 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophageal Neoplasm
Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer
In patients with esophageal cancer, treatment with curative intent can be given to medically fit patients without distant metastases. It may consist of chemoradiotherapy or surgery alone or in combination.
- Trial name
- LERFOX-C (NCT02636088)
- Testing
- Cetuximab
- Volunteers
- 51 people
- Sponsor
- Gabriella Alexandersson von Döbeln
Carcinomas of the Esophagogastric Junction
Esophagogastrectomy Versus Extended Gastrectomy in AEG II
Comparison of the oncological outcome of patients who underwent esophagogastrectomy versus extended gastrectomy due to carcinomas of the esophagogastric junction (Siewert type II)
- Trial name
- AEG-II-EG (NCT02302118)
- Testing
- Esophagogastrectomy
- Where
- Germany
- Volunteers
- 128 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Esophageal Squamous Cell Carcinoma
Tumor Microenvironment Changes After Neoadjuvant Chemo-Immunotherapy in Esophageal Squamous Cell Carcinoma
This prospective observational study aims to characterize dynamic changes in the tumor microenvironment of patients with esophageal squamous cell carcinoma receiving standard neoadjuvant chemotherapy combined with immunotherapy…
- Trial name
- TME-ESCC (NCT07482774)
- Testing
- Biological: Tumor Tissue and Blood Sample Collection
- Volunteers
- 12 people
- Sponsor
- Nanjing Medical University
Esophageal Cancer
Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Trial name
- NCT00004897
- Testing
- recombinant interferon alfa, cisplatin, fluorouracil
- Where
- United States
- Sponsor
- Northwestern University
Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma
Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer
This randomized study examines how well zinc works in improving quality of life in patients with gastrointestinal cancer that cannot be removed by surgery who are receiving chemotherapy.
- Conditions
- Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Unresectable Esophageal Carcinoma, Unresectable Pancreatic Carcinoma
- Trial name
- NCT03819088
- Testing
- Zinc
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Emory University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.